← All trials
NCT01913535
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2015
- Primary completion
- Oct 1, 2016
- Completion date
- Dec 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 91
- Arms / groups
- 5 / —
- Source
- AACT · pre-existing
Sponsors
- Harvard UniversityLead sponsor
- Temple UniversityOverall official - principal investigator
- Rush UniversityOverall official - principal investigator
- Brown UniversityOverall official - principal investigator
- Harvard UniversityOverall official - principal investigator
- Harvard UniversityReponsible party - principal investigator
- National Institute of Mental Health (NIMH)Collaborator
- Temple UniversityCollaborator
- Brown UniversityCollaborator
- Rush UniversityCollaborator
- University of KansasOverall official - principal investigator
- University of KansasCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.